Innovative gene delivery systems for retinal disease therapy

Area of Science:

• Ophthalmology and Gene Therapy
• Biomedical Engineering and Drug Delivery

Background:

• Retinal damage from genetic factors or degeneration causes vision impairment and blindness.
• Current treatments for retinal diseases are limited, highlighting the need for innovative therapeutic strategies.
• Cell and gene therapies show promise for retinal repair and vision restoration.

Purpose of the Study:

• To review and compare viral and non-viral gene delivery systems for retinal disease treatment.
• To detail the characteristics, advantages, limitations, and clinical applications of various vector types.
• To guide the selection of optimal delivery tools for specific retinal diseases to enhance therapeutic efficacy.

Main Methods:

• Review of viral gene delivery vectors: lentiviruses and adeno-associated viruses.
• Exploration of non-viral gene delivery systems: liposomal technology, solid lipid nanoparticles, polymer nanoparticles, dendrimers, and polymeric micelles.
• Systematic analysis of vector properties, including packaging capacity, integration risks, loading capacity, and immunogenicity.

Main Results:

• Viral vectors (lentiviruses, AAVs) offer efficient gene delivery but have limitations like integration risks or packaging capacity.
• Non-viral systems, especially liposomal-based ones, provide higher loading capacities for direct nucleic acid/protein delivery.
• Non-viral systems require optimization to mitigate potential immunogenicity and toxicity for in vivo applications.

Conclusions:

• Both viral and non-viral gene delivery systems have distinct advantages and limitations for treating retinal diseases.
• Careful selection of the appropriate delivery vector is crucial for maximizing treatment efficacy and patient outcomes.
• Continued development of novel delivery systems is essential for advancing targeted retinal therapies and vision restoration.